If blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 64-73

  Scheruebel, Susanne ^a   Koyani, Chintan N ^a   Hallström, Seth ^a   Lang, Petra ^a   Platzer, Dieter ^a   Mächler, Heinrich ^a   Lohner, Karl ^b   Malle, Ernst ^a   Zorn Pauly, Klaus ^a   Pelzmann, Brigitte ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

HCN channel; Human pacemaker current; Ivabradine; Lipopolysaccharide; Patch clamp; Sinoatrial cell model

Indexed keywords

ENDOTOXIN; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL 2; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL 4; IVABRADINE; UNCLASSIFIED DRUG; BENZAZEPINE DERIVATIVE; HCN2 PROTEIN, HUMAN; HCN4 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; MUSCLE PROTEIN; POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; ATRIAL PACEMAKER CURRENT; CHANNEL GATING; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG EFFICACY; GUINEA PIG; HEART MUSCLE CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SINUS NODE; ACTION POTENTIAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); CYTOLOGY; DRUG EFFECTS; HEART ATRIUM; HEART RATE; METABOLISM; PATCH CLAMP TECHNIQUE; PRIMARY CELL CULTURE;

ACTION POTENTIALS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; HEART ATRIA; HEART RATE; HUMANS; HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS; LIPOPOLYSACCHARIDES; MODELS, BIOLOGICAL; MUSCLE PROTEINS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PRIMARY CELL CULTURE; SINOATRIAL NODE;

EID: 84901229197     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.02.010     Document Type: Article

References (58)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
2. Fernandes C.J., de Assuncao M.S. Myocardial dysfunction in sepsis: a large, unsolved puzzle. Crit Care Res Pract 2012, 2012:896430.
3. Hoke R.S., Müller-Werdan U., Lautenschlager C., Werdan K., Ebelt H. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol 2012, 101:139-147.
4. Huber M., Kalis C., Keck S., Jiang Z., Georgel P., Du X., et al. R-form LPS, the master key to the activation of TLR4/MD-2-positive cells. Eur J Immunol 2006, 36:701-711.
5. Seydel U., Hawkins L., Schromm A.B.., Heine H., Scheel O., Koch M.H., et al. The generalized endotoxic principle. Eur J Immunol 2003, 33:1586-1592.
6. Brandenburg K., Wiese A. Endotoxins: relationships between structure, function, and activity. Curr Top Med Chem 2004, 4:1127-1146.
7. Nielsen J.S., Larsson A., Ledet T., Turina M., Tonnesen E., Krog J. Rough-form-lipopolysaccharide increase apoptosis in human CD4(+) and CD8(+) T-lymphocytes. Scand J Immunol 2012, 75:193-202.
8. + channel in transmembrane signaling. J Immunol 2001, 166:1009-1015.
9. + channels at the intracellular membrane face of rat cerebral artery smooth muscle cells. Neurosci Lett 1997, 231:25-28.
10. Wilkinson M.F., Earle M.L., Triggle C.R., Barnes S. Interleukin-1beta, tumor necrosis factor-alpha, and LPS enhance calcium channel current in isolated vascular smooth muscle cells of rat tail artery. FASEB J 1996, 10:785-791.
11. Biel M., Wahl-Schott C., Michalakis S., Zong X. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev 2009, 89:847-885.
12. Bucchi A., Barbuti A., DiFrancesco D., Baruscotti M. Funny current and cardiac rhythm: insights from HCN knockout and transgenic mouse models. Front Physiol 2012, 3:240.
13. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010, 106:434-446.
14. f. Shock 2007, 28:655-661.
15. Papaioannou V.E., Verkerk A.O., Amin A.S., de Bakker J.M. Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness. Curr Cardiol Rev 2013, 9:82-96.
16. Klöckner U., Rueckschloss U., Grossmann C., Ebelt H., Müller-Werdan U., Loppnow H., et al. Differential reduction of HCN channel activity by various types of lipopolysaccharide. J Mol Cell Cardiol 2011, 51:226-235.
17. f in immortalized HL-1 cardiomyocytes. Am J Physiol Cell Physiol 2010, 299:C665-C671.
18. Schmidt H., Hoyer D., Hennen R., Heinroth K., Rauchhaus M., Prondzinsky R., et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med 2008, 36:967-970.
19. f (funny channel current) inhibitor ivabradine: MODI(f)Y trial. Clin Res Cardiol 2011, 100:915-923.
20. Bois P., Bescond J., Renaudon B., Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996, 118:1051-1057.
21. f inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther 2011, 9:959-973.
22. f channel inhibitor in the treatment of stable angina. Int J Clin Pract 2006, 60:222-228.
23. Bucchi A., Tognati A., Milanesi R., Baruscotti M., DiFrancesco D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 2006, 572:335-346.
24. Speranza L., Franceschelli S., Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules 2012, 17:4924-4935.
25. World Medical Association General Assembly World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004, 15:124-129.
26. Pelzmann B., Schaffer P., Mächler H., Rigler B., Koidl B. Adenosine inhibits the L-type calcium current in human atrial myocytes. Naunyn Schmiedebergs Arch Pharmacol 1995, 351:293-297.
27. Piper H.M., Probst I., Schwartz P., Hutter F.J., Spieckermann P.G. Culturing of calcium stable adult cardiac myocytes. J Mol Cell Cardiol 1982, 14:397-412.
28. Claycomb W.C., Lanson N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 1998, 95:2979-2984.
29. f in single human atrial myocytes and the effect of beta-adrenoceptor and A1-adenosine receptor stimulation. Br J Pharmacol 1997, 122:963-969.
30. Barry P.H. JPCalc, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial and bilayer measurements and for correcting junction potential measurements. J Neurosci Methods 1994, 51:107-116.
31. Kitz K., Windischhofer W., Leis H.J., Huber E., Kollroser M., Malle E. 15-Deoxy-δ12,14-prostaglandin J2 induces Cox-2 expression in human osteosarcoma cells through MAPK and EGFR activation involving reactive oxygen species. Free Radic Biol Med 2011, 50:854-865.
32. Rossmann C., Rauh A., Hammer A., Windischhofer W., Zirkl S., Sattler W., et al. Hypochlorite-modified high-density lipoprotein promotes induction of HO-1 in endothelial cells via activation of p42/44 MAPK and zinc finger transcription factor Egr-1. Arch Biochem Biophys 2011, 509:16-25.
33. Semlitsch M., Shackelford R.E., Zirkl S., Sattler W., Malle E. ATM protects against oxidative stress induced by oxidized low-density lipoprotein. DNA Repair (Amst) 2011, 10:848-860.
34. Klippert P., Jeanniot J.P., Polve S., Lefevre C., Merdjan H. Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998, 719:125-133.
35. Severi S., Fantini M., Charawi L.A., DiFrancesco D. An updated computational model of rabbit sinoatrial action potential to investigate the mechanisms of heart rate modulation. J Physiol 2012, 590:4483-4499.
36. f inhibition in cardiovascular diseases. Adv Pharmacol 2010, 59:53-92.
37. f in human atrial myocytes. J Cardiovasc Electrophysiol 2007, 18:1190-1196.
38. Postea O., Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov 2011, 10:903-914.
39. Ulevitch R.J., Johnston A.R., Weinstein D.B. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981, 67:827-837.
40. Wondergem R., Graves B.M., Li C., Williams D.L. Lipopolysaccharide prolongs action potential duration in HL-1 mouse cardiomyocytes. Am J Physiol Cell Physiol 2012, 303:C825-C833.
41. Cardoso F.L., Kittel A., Veszelka S., Palmela I., Toth A., Brites D., et al. Exposure to lipopolysaccharide and/or unconjugated bilirubin impair the integrity and function of brain microvascular endothelial cells. PLoS One 2012, 7:e35919.
42. Werdan K., Schmidt H., Ebelt H., Zorn-Pauly K., Koidl B., Hoke R.S., et al. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 2009, 87:266-274.
43. Kumar A., Krieger A., Symeoneides S., Kumar A., Parrillo J.E. Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. J Cardiothorac Vasc Anesth 2001, 15:485-511.
44. Hunter J.D., Doddi M. Sepsis and the heart. Br J Anaesth 2010, 104:3-11.
45. Fischmeister R., Castro L., Abi-Gerges A., Rochais F., Vandecasteele G. Species-and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 2005, 142:136-143.
46. Aoki Y., Hatakeyama N., Yamamoto S., Kinoshita H., Matsuda N., Hattori Y., et al. Role of ion channels in sepsis-induced atrial tachyarrhythmias in guinea pigs. Br J Pharmacol 2012, 166:390-400.
47. Musialek P., Lei M., Brown H.F., Paterson D.J., Casadei B. Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). Circ Res 1997, 81:60-68.
48. Knuefermann P., Sakata Y., Baker J.S., Huang C.H., Sekiguchi K., Hardarson H.S., et al. Toll-like receptor 2 mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 2004, 110:3693-3698.
49. Boehm O., Knuefermann P., Plueck J., Schwederski M., Ehrentraut H., Kebir S., et al. TLR2 stimulation induces cardiac inflammation but not cardiac depression in vivo. J Inflamm (Lond) 2013, 10:33.
50. Stadler K., Bierwirth C., Stoenica L., Battefeld A., Reetz O., Mix E., et al. Elevation in type I interferons inhibits HCN1 and slows cortical neuronal oscillations. Cereb Cortex 2014, 24:199-210.
51. Thollon C., Bedut S., Villeneuve N., Coge F., Piffard L., Guillaumin J.P., et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol 2007, 150:37-46.
52. Koncz I., Szel T., Bitay M., Cerbai E., Jaeger K., Fulop F., et al. Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions. Eur J Pharmacol 2011, 668:419-426.
53. Delcour A.H. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 2009, 1794:808-816.
54. Tsujimoto H., Gotoh N., Nishino T. Diffusion of macrolide antibiotics through the outer membrane of Moraxella catarrhalis. J Infect Chemother 1999, 5:196-200.
55. f, in mathematical models of rabbit sinoatrial node pacemaker cells. Biomed Res Int 2013, 2013:872454.
56. Monfredi O., Maltsev V.A., Lakatta E.G. Modern concepts concerning the origin of the heartbeat. Physiology (Bethesda) 2013, 28:74-92.
57. De Santis V., Vitale D., Santoro A., Magliocca A., Porto A.G., Nencini C., et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol 2013, 102:171-178.
58. Parker M.M., Shelhamer J.H., Natanson C., Alling D.W., Parrillo J.E. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987, 15:923-929.